Bryce Point Capital LLC Invests $583,000 in Insmed, Inc. $INSM

Bryce Point Capital LLC acquired a new stake in Insmed, Inc. (NASDAQ:INSM) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 5,793 shares of the biopharmaceutical company’s stock, valued at approximately $583,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Corton Capital Inc. acquired a new stake in Insmed in the second quarter valued at $393,000. Amalgamated Bank boosted its position in shares of Insmed by 117.3% in the 2nd quarter. Amalgamated Bank now owns 12,973 shares of the biopharmaceutical company’s stock worth $1,306,000 after buying an additional 7,003 shares in the last quarter. Atria Investments Inc grew its stake in Insmed by 75.3% in the 2nd quarter. Atria Investments Inc now owns 16,810 shares of the biopharmaceutical company’s stock valued at $1,692,000 after acquiring an additional 7,219 shares during the last quarter. Assetmark Inc. increased its holdings in Insmed by 22.5% during the 2nd quarter. Assetmark Inc. now owns 32,125 shares of the biopharmaceutical company’s stock valued at $3,233,000 after acquiring an additional 5,892 shares in the last quarter. Finally, Keybank National Association OH increased its holdings in Insmed by 14.2% during the 2nd quarter. Keybank National Association OH now owns 9,459 shares of the biopharmaceutical company’s stock valued at $952,000 after acquiring an additional 1,179 shares in the last quarter.

Insider Transactions at Insmed

In other news, COO Roger Adsett sold 25,000 shares of the stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the transaction, the chief operating officer directly owned 105,637 shares in the company, valued at $13,477,168.46. This represents a 19.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO William Lewis sold 6,865 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $128.40, for a total transaction of $881,466.00. Following the completion of the sale, the chief executive officer owned 233,924 shares of the company’s stock, valued at approximately $30,035,841.60. The trade was a 2.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 152,657 shares of company stock worth $21,442,198 in the last quarter. 3.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

INSM has been the topic of several recent research reports. TD Cowen upped their price target on shares of Insmed from $154.00 to $193.00 and gave the company a “buy” rating in a report on Thursday, October 2nd. Cantor Fitzgerald started coverage on Insmed in a research note on Tuesday, October 28th. They issued an “overweight” rating and a $192.00 target price on the stock. Jefferies Financial Group increased their target price on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, August 13th. UBS Group raised their price target on Insmed from $194.00 to $223.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Truist Financial upped their price objective on Insmed from $126.00 to $139.00 and gave the company a “buy” rating in a research report on Thursday, August 14th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Insmed presently has an average rating of “Moderate Buy” and an average target price of $173.29.

Insmed Stock Down 1.9%

INSM stock opened at $182.77 on Wednesday. The stock has a market capitalization of $38.63 billion, a P/E ratio of -32.01 and a beta of 1.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. Insmed, Inc. has a one year low of $60.40 and a one year high of $197.08. The company has a 50 day moving average price of $154.19 and a two-hundred day moving average price of $114.25.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The business had revenue of $142.34 million for the quarter, compared to analysts’ expectations of $114.33 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.